"Cilastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, IMIPENEM, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4.
- MK 0791
- MK 791
- Cilastatin Sodium
- Sodium, Cilastatin
- Cilastatin Monosodium Salt
- Monosodium Salt, Cilastatin
- Salt, Cilastatin Monosodium
Below are MeSH descriptors whose meaning is more general than "Cilastatin".
Below are MeSH descriptors whose meaning is more specific than "Cilastatin".
This graph shows the total number of publications written about "Cilastatin" by people in this website by year, and whether "Cilastatin" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Cilastatin" by people in Profiles.
Wang X, Liu N, Wei Y, Zhang S, Li H, Yan B, Patel M, Wang H, Boundy KE, Colon-Gonzalez F, Zang Y, Zhao X. A Single- and Multiple-Dose Study To Characterize the Pharmacokinetics, Safety, and Tolerability of Imipenem and Relebactam in Healthy Chinese Participants. Antimicrob Agents Chemother. 2021 02 17; 65(3).
Bhagunde P, Colon-Gonzalez F, Liu Y, Wu J, Xu SS, Garrett G, Jumes P, Lasseter K, Marbury T, Rizk ML, Lala M, Rhee EG, Butterton JR, Boundy K. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin. Br J Clin Pharmacol. 2020 05; 86(5):944-957.